30O.F ONCOTHERAPY SCIENCE INC.

Healthcare Biotechnology Frankfurt Exchange
0.0710 EUR
Close of Nov 11, 2026
0.0640 0.1640
Market cap
EUR 29.0M
P/E
-
P/B
2.19x
ROE
-49.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 30O.F undervalued?

Graham number

The Graham number of ONCOTHERAPY SCIENCE INC. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONCOTHERAPY SCIENCE INC. fundamental analysis

No fundamental analysis for ONCOTHERAPY SCIENCE INC. yet.

ONCOTHERAPY SCIENCE INC. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONCOTHERAPY SCIENCE INC.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast canc…

Full company profile